INTRODUCTION
Maternal alloimmunisation to paternally-inherited alloantigens on red cells or platelets can cause pregnancy complications which threaten the life of the fetus.
Involvement of Fc receptors for IgG (Fc R) in destruction of alloantibody-coated blood cells is suggested by studies in which antibody-mediated haemolysis was inhibited by antibodies against Fc R.
1 Although the timing of appearance of Fc R on fixed effector cells in fetal liver and spleen is uncertain, Fc RI-III are present on circulating leucocytes by 18 weeks of pregnancy 2 , when alloimmunity can cause life-threatening fetal platelet destruction. 3 In contrast to IgG1 and IgG3, IgG2 and IgG4 antibodies rarely cause significant ), some mutated constant regions resulted in antibodies with minimal binding to Fc RI and III and less capacity for cell lysis than IgG2 or IgG4. 7, 8 In particular, Fog-1 G1 ab-coated red cells did not trigger either CD16-positive NK cell-mediated cytotoxicity (ADCC) 8 or monocyte chemiluminescence (CL) 7 , an assay reported to predict clinical outcome in haemolytic disease of the newborn (HDN) 9 .
Importantly, Fog-1 G1 ab inhibited ADCC and CL triggered either by Fog-1 IgG1
or clinical anti-D sera. 7, 8 Fog-1 G1 ab has been further modified by removal of three allotypic residues 10 and redesignated Fog-1 G1 nab. 11 , were coated with either active Fog-1 G1 or mutated Fog-1 G1 nab.
Since radiolabelling and antibody sensitisation do not affect each other 12, 13 , this dual labelling strategy provides comparative red cell survival data for the two antibodies without the added complexity of inter-donor variation. It permits assessment of both intravascular survival beyond a few hours ( 51 Cr) and sites of red cell destruction by gamma camera imaging ( 99m Tc) 13 . 
SOL-ELISA for measurement of antibody coating
Known volumes of antibody-coated red cells were solubilised 19 and antibody standard prepared in the same buffer. Dilutions were assayed in quadruplicate in a sandwich ELISA using unlabelled and peroxidase-conjugated goat anti-human chain antibodies (Sigma, Poole, UK). Mean absorbance was plotted against amount of antibody/volume of lysate (log scale). The standard deviations of the means were used to obtain equations for the minimum and maximum versions of the linear portions of the curves. This allowed calculation of the minimum and maximum amounts of standard antibody and lysate corresponding to the midpoint absorbance value. These were equated and converted to antibody molecules per cell. The result was given as the midpoint, with the range expressed as an estimated error.
Radiolabelling/antibody coating for subjects 1 -5
On the day of study, a 17 ml citrated blood sample taken and split into 2 aliquots.
Packed red cells from each aliquot were separately radiolabelled with either 1.2
MBq 51
Cr sodium chromate or stannous medronate solution followed by 60 MBq 99m Tc sodium pertechnetate by incubation for 15 minutes at room temperature.
After washing, the aliquots were incubated with Fog-1 G1 or G1 nab (8 ml of antibody at 50µg/ml) for 30 minutes at 37 o C, consecutive subjects having opposite radiolabel/antibody combinations. After washing, each aliquot was resuspended to 9.5 ml in saline, providing 8 ml for re-injection, plus samples for a counting standard and SOL-ELISA. The injected activities were 0. Cr from the cells. 21 To calculate clearance rates of labelled cells from the blood, whole blood activity was corrected for plasma activity, using the sample haematocrit, to give cell-bound activity. The data were transformed logarithmically, and the curves from 5 -60 min were fitted with a standard least squares routine (Excel, Microsoft, Seattle USA). Data from the 0 -300 min time points of the Fog-1 G1Enab clearance curves were also fitted to the function: C(t) = A + B exp(-bt) using a non-linear least squares routine (IDL Research Systems, Boulder, USA).
Gamma camera imaging (subjects 1 -5)
Gamma camera imaging was performed with the subject lying supine under a dual-headed gamma camera (Prism 2000XP, Picker, Ohio, USA) positioned over the chest and upper abdomen. Dynamic imaging (40 x 1 min frames) was performed immediately after injection followed by static imaging at 40 min. Count rates for regions drawn around the whole liver, whole spleen and a portion of right lung were corrected for background and geometric means of anterior and posterior views of each organ were calculated. These means were normalised to a standard injected activity and time-activity curves plotted.
Survival and gamma camera imaging of Fog-1 G1 nab-coated cells (subject 6)
To assess whether Fog-1 G1 nab-coated RBC were accumulating on microvascular endothelium, a revised protocol was developed for subject 6, using a modification of a method previously described for neutrophils 
RESULTS

Clinical effects and red cell antibody coating
Subjects 1 -5 were studied within a 6-week time frame. The injections were generally well tolerated, with no symptoms reported on the day of study and no changes in pulse, temperature or blood pressure in subjects 1 -4. However, at follow-up, subject 4 reported having felt shivery 1 hour post-injection and 'achey' the following day, returning to normal by 48 hours. SOL-ELISA results showed that the degree of red cell coating by Fog-1 G1 and G1 nab ranged from 6,500 -19,900 molecules/cell in the different subjects (Table 1 ). The maximum amount of total antibody received was 130 -430 µg.
The degree of coating showed only limited correlation with Rh phenotype, with considerable overlap between D homozygous and heterozygous individuals.
Importantly, coating levels for the two antibodies were within 4% of each other for subjects 1, 2, 3 and 5 and within 10% for subject 4. Thus, direct comparison of intravascular survival of red cells coated with wildtype and modified antibodies was considered valid.
Recovery and survival of antibody coated red cells in subjects 1 -5
For the majority of injections, there was less than 100% recovery of radiolabelled cells coated with either antibody as determined from whole blood counts of samples taken 1.5 -5 min after injection ( Figure 1 , Table 2 ). The exception was
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From the Fog-1 G1-coated red cells in subject 5, where 101% injected dose was measured at 1.5 min. In the other subjects, the maximum recovery of G1-coated cells ranged from 73 -84% while 78 -91% G1Enab-coated cells were recovered in the five subjects.
Cells coated with Fog-1 G1 were removed rapidly from the circulation in all five subjects, with complete clearance by 200 minutes and no reappearance at later time points (Figures 1a, 2a) . The rate constant of clearance of cells coated with Fog-1 G1, calculated from the 5 -60 min data for cell-associated activity ( Figure   2a ), ranged from 0.026 -0.046 min -1 ( (Table 2 ) and were significantly lower than the G1 values of 0.026 -0.046 (Student's t-tests: unpaired p=0.008, paired p=0.0002). However, since the cell-associated activity curves approached plateaux towards the end of the 0 -300 min period (Figure 2b ), these data were better described by the function C(t) = A + B exp(-bt) , allowing estimation of a rate constant (b) for the disappearance of a portion of cells and a plateau value (A) representing the level remaining in circulation (Table 2 ). This second rate constant, for which there is no corresponding value for G1-coated cells, ranged from 0.020 -0.030 min -1 and the plateau value from 6 -40%, neither value correlating with either Rh phenotype or level of coating.
For
Cr is a stable red cell label 11 , non-cell-bound activity is a marker of cell destruction. For G1-coated cells, the plasma 51 Cr curves were consistent with complete cell destruction, as suggested by the rapid disappearance of the whole blood signal, and peaked at 4.5 and 6.1% injected dose ( Figure 3 , Table 2 
Organ scanning
Uptake of 99m Tc-labelled, antibody-coated cells by the spleen and liver over the first 40 min post-injection was monitored by gamma camera imaging for subjects 1 -5. In all subjects, the cells accumulated in the spleen, although uptake tended to be higher in the three subjects with the 99m Tc/Fog-1 G1 combination ( Figure 4) . Two of these subjects (1 and 5) also showed increased activity over the liver which was not apparent for subject 3 (Fog-1 G1) or for subjects 2 and 4 (G1Enab). In all subjects, a low count rate was recorded over the lungs, excluding the possibility of adhesion of cells to pulmonary vascular endothelium.
Investigation of early loss of injected cells
The protocol used for subject 6 was designed to investigate whether the apparent loss of cells immediately upon injection was due to adhesion to microvascular endothelium. Unexpectedly, two of our subjects had mild febrile reactions coincidental with the appearance of radiolabel in the plasma, suggesting a response to the destructive process. The previous study of active Fog-1 reported no reactions 27 , but the volumes of coated cells were nearly 20 times lower than injected here. Since the two febrile subjects had both wildtype and modified antibody, it is not possible to attribute the reactions to either one.
The key finding of the study is that there was a clear difference between the survival curves for cells coated with wildtype IgG1 and mutant G1 nab antibodies.
The clearance of cells coated with Fog-1 G1 antibody was rapid, with a fall of at least 70% between 5 and 60 min, and was essentially complete by 3 hours to promote faster and more complete haemolysis than in the earlier study may be due to the different expression system used here. The original Fog-1 was obtained from human-mouse heterohybridoma cells whereas we used rat myeloma cells for the production of recombinant Fog-1 G1 and G1 nab. showing no hepatic uptake with IgG1 which was probably due to the low coating level (6,800 molecules/cell), since hepatic uptake has not been detected with less than 9000 IgG anti-D molecules per cell. 12,13 These differences are not due to G1Enab being lost from the cells faster than wildtype antibody since, as expected for antibodies containing the same variable regions, elution rates and titration curves against D homozygous and heterozygous cells were identical.
These results suggest that G1 nab-coated cells are not destroyed but show exaggerated pooling within the spleen, adhering to splenic Fc R but not triggering signalling and phagocytosis. Binding to Fc RII may be the explanation, since, although the mutations have abrogated binding to Fc RI and III 7, 8 , some interaction with Fc RIIa and the inhibitory receptor Fc RIIb remains. 16 The clearance curves from 5 -300 minutes could be described in terms of a rate constant for the clearance of a proportion of cells and a plateau value which limits the clearance in this period. This has some similarities with the biexponential clearance kinetics observed for heat-damaged red cells, which are either
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From temporarily sequestered in the spleen or permanently trapped and destroyed. 13 Our observations are also consistent with the biphasic model of sequestration In four subjects, for cells coated with either antibody, less than 100% injected dose of radiolabel was detected in the blood at the earliest time points. It is unclear whether this was seen previously with Fog-1, since survival results were expressed as a percentage of the 3 min sample
27
. The discrepancy could be partly explained by an underestimation of blood volume, since there is up to 25%
error in blood volumes calculated from height and weight
20
, but it seems unlikely that the actual volume would be higher than predicted in every subject tested.
Rapid cell clearance by an individual organ was considered, but none has blood flow high enough to account for the degree and speed of loss. Using Fog-1 G1 nab in subject 6, we examined whether adhesion to capillary endothelium throughout the vasculature could be rendering cells unavailable for sampling.
However, comparison of the blood counts relative to the soft tissue signal between uncoated and Fog-1 G1 nab-coated cells did not support this hypothesis ( Figure 5 ), and early losses of cells remain unexplained. These disparities do not affect the overall conclusions of the study, since we have compared survival of the two cell populations simultaneously in each donor.
We wished to achieve 100% saturation of D sites on the red cells, to mimic the worst case scenario in HDN. The concentration of antibody this required could not be attained for Fog-1 G1Enab due to purification limitations, so we compared clearance at a calculated 75% saturation for both wildtype and mutated antibodies. Although the degree of coating achieved varied considerably between subjects, the variation in coating between the two antibodies in each individual was small enough to permit a valid paired comparison of red cell survival (Table   1 ). We saw no clear correlation between the degree of coating and Rh phenotype. Subject 3, in particular, showed surprisingly low coating for an apparently homozygous individual (Table 1) . Since we performed Rh phenotyping and not genotyping, it is possible that this subject has the rare genotype Rzr, rather than the common R 1 R 2 , and is thus heterozygous for D. 
Figure 4
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